| 臺大學術典藏 |
2022-02-18T08:46:50Z |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
|
Liou J.-M.; Fang Y.-J.; CHIEN-CHUAN CHEN; Bair M.-J.; Chang C.-Y.; Lee Y.-C.; Chen M.-J.; CHIEN-CHUAN CHEN; Tseng C.-H.; Hsu Y.-C.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hu W.-H.; Chen Y.-N.; Sheu B.-S.; Lin J.-T.; Wu J.-Y.; El-Omar E.M.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-18T08:46:45Z |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial
|
Liou J.-M.; CHIEN-CHUAN CHEN; Chang C.-M.; Fang Y.-J.; Bair M.-J.; Chen P.-Y.; Chang C.-Y.; Hsu Y.-C.; Chen M.-J.; CHIEN-CHUAN CHEN; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chen C.-Y.; Hsu W.-F.; Chen Y.-N.; Wu J.-Y.; Lin J.-T.; Lu T.-P.; Chuang E.Y.; El-Omar E.M.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-18T08:26:07Z |
The primary resistance of Helicobacter pylori in Taiwan after the national policy to restrict antibiotic consumption and its relation to virulence factors - A nationwide study
|
Liou J.-M.; Chang C.-Y.; Chen M.-J.; CHIEH-CHANG CHEN; Fang Y.-J.; Lee J.-Y.; Wu J.-Y.; Luo J.-C.; Liou T.-C.; Chang W.-H.; Tseng C.-H.; Wu C.-Y.; Yang T.-H.; Chang C.-C.; Wang H.-P.; Sheu B.-S.; Lin J.-T.; Bair M.-J.; Wu M.-S.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Lee Y.-C.; Wang Y.-C.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-18T08:26:06Z |
Levofloxacin sequential therapy vs levofloxacin triple therapy in the second-line treatment of helicobacter pylori: A randomized trial
|
Liou J.-M.; Bair M.-J.; CHIEH-CHANG CHEN; Lee Y.-C.; Chen M.-J.; CHIEH-CHANG CHEN; Tseng C.-H.; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Chang W.-H.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hung H.-W.; Lin J.-T.; Chang C.-Y.; Wu M.-S. |
| 臺大學術典藏 |
2022-02-18T08:26:06Z |
Distinct aetiopathogenesis in subgroups of functional dyspepsia according to the Rome III criteria
|
Fang Y.-J.; Liou J.-M.; CHIEH-CHANG CHEN; Lee J.-Y.; Hsu Y.-C.; Chen M.-J.; Tseng P.-H.; CHIEH-CHANG CHEN; Chang C.-Y.; Yang T.-H.; Chang W.-H.; Wu J.-Y.; Wang H.-P.; Luo J.-C.; Lin J.-T.; Shun C.-T.; Wu M.-S. |
| 臺大學術典藏 |
2022-02-18T08:26:05Z |
Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: A randomised trial
|
Liou J.-M.; CHIEH-CHANG CHEN; Chang C.-Y.; Chen M.-J.; CHIEH-CHANG CHEN; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Liou T.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Chang C.-C.; Bair M.-J.; Liu T.-Y.; Hsieh C.-F.; Tsao F.-Y.; Shun C.-T.; Lin J.-T.; Lee Y.-C.; Wu M.-S.; the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-18T08:26:05Z |
Association Between Serum Level of Hepatitis B Surface Antigen at End of Entecavir Therapy and Risk of Relapse in E Antigen–Negative Patients
|
Hsu Y.-C.; Mo L.-R.; Chang C.-Y.; Wu M.-S.; Kao J.-H.; Wang W.-L.; Yang T.-H.; Wang C.-S.; Chiang M.-F.; CHIEH-CHANG CHEN; Fang Y.-J.; Hung H.-W.; Wu C.-Y.; Lin J.-T. |
| 臺大學術典藏 |
2022-02-18T08:26:04Z |
Serum viral load at the virological relapse predicts subsequent clinical flares in chronic hepatitis B patients off entecavir therapy
|
Hsu Y.-C.; Mo L.-R.; Chang C.-Y.; Wu M.-S.; Yang T.-H.; Kao J.-H.; CHIEH-CHANG CHEN; Tseng C.-H.; Tai C.-M.; Lin C.-W.; Wu C.-Y.; Lin J.-T. |
| 臺大學術典藏 |
2022-02-18T08:26:04Z |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
|
Liou J.-M.; Fang Y.-J.; CHIEH-CHANG CHEN; Bair M.-J.; Chang C.-Y.; Lee Y.-C.; Chen M.-J.; CHIEH-CHANG CHEN; Tseng C.-H.; Hsu Y.-C.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hu W.-H.; Chen Y.-N.; Sheu B.-S.; Lin J.-T.; Wu J.-Y.; El-Omar E.M.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-18T08:26:02Z |
14 Day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: A multicentre, non-inferiority, randomized trial
|
Liou J.-M.; CHIEH-CHANG CHEN; Fang Y.-J.; Chen P.-Y.; Chang C.-Y.; Chou C.-K.; Chen M.-J.; Tseng C.-H.; Lee J.-Y.; Yang T.-H.; Chiu M.-C.; Yu J.-J.; Kuo C.-C.; Luo J.-C.; Hsu W.-F.; Hu W.-H.; Tsai M.-H.; Lin J.-T.; Shun C.-T.; Twu G.; Lee Y.-C.; Bair M.-J.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
